Business Information
The group's principal activities are to develop treatments for cancers, serious infectious diseases, autoimmune disorders and degenerative disorders using proprietary technologies to program the immune system and to improve quality of life. The group primarily develops immunotherapeutics, including lead product and oncophage (r). Lead development programs include immunotherapeutics that are based on a specific class of proteins known as heat shock proteins (hsps) and an immune system adjuvant called qs-21. The products under development include oncophage (R), aroplatin, atra-iv, ag-702, qs-21 adjuvant, CD91 and CD1. The related business activities include product research and development activities, regulatory and clinical affairs, establishing manufacturing capabilities, production for clinical trials and administrative and corporate development activities.
|
|
Name |
Title
|
Email
|
| Garo Armen | Chmn., CEO | N/A | | Pierre Champagne | Head - Clinical, Medical Affairs | N/A | | Shalini Sharp | CFO, VP | N/A | | Deanna Petersen | VP - Business Development | N/A | | John Cerio | VP - Human Resources | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 692 | (51,881) | | 2005 | 630 | (74,104) | | 2004 | 707 | (56,162)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
